The role of ATP synthase subunit e (ATP5I) in mediating the metabolic and antiproliferative effects of metformin in cancer cells
Open Access
- 15 May 2026
- journal article
- research article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 13
Abstract
Here, we identify the subunit e of F₁F₀-ATP synthase (ATP5I) as a target of metformin, a first-in-class antidiabetic biguanide. ATP5I maintains the stability of F₁F₀-ATP synthase dimers, which is crucial for shaping cristae morphology. We demonstrate that ATP5I interacts with a biguanide analogue in vitro, and disabling its expression by CRISPR–Cas9 in pancreatic cancer cells leads to the same phenotype as biguanide-treated cells, including mitochondrial morphology alterations, reduction of the NAD + /NADH ratio, inhibition of oxidative phosphorylation (OXPHOS), rescue of respiration by uncouplers, and a compensatory increase in glycolysis. Notably, metformin disrupts F₁F₀-ATP synthase oligomerization, leading to the accumulation of vestigial assembly intermediates in pancreatic and osteosarcoma cancer cells, a phenotype also observed upon ATP5I inactivation in pancreatic cancer cells. Moreover, ATP5I knockout (KO) cells exhibit resistance to the antiproliferative effects of biguanides, but reintroduction of ATP5I rescues the metabolic and antiproliferative effects of metformin and phenformin. Finally, a genome-wide CRISPR screening in NALM-6 lymphoma cells revealed that metformin-treated cells exhibit genetic interaction profiles similar to those observed with the F₁F₀-ATP synthase inhibitor oligomycin, but not with the complex I inhibitor rotenone. This provides unbiased support for the relevance of the newly proposed target.Keywords
All Related Versions
Funding Information
- Terry Fox Research Institute (TFRI Project #1123)
- Cancer Research Society (Operating Grant 2016)
- Cancer Research Society (935858)
- Cancer Research Society (840633)
- Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03128)
- Cancer Research Society (Ganotec/Marc-André Pigeon Fund)
- Cancer Research Society (1054571)
This publication has 89 references indexed in Scilit:
- Characterization of Small Molecule–Protein Interactions Using SPR Method2023
- First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancerInvestigational New Drugs, 2021
- Metformin regulates mitochondrial biogenesis and senescence through AMPK mediated H3K79 methylation: Relevance in age-associated vascular dysfunctionBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2018
- Metformin: historical overviewDiabetologia, 2017
- Relevance of the OCT1 transporter to the antineoplastic effect of biguanidesBiochemical and Biophysical Research Communications, 2011
- Cristae formation—linking ultrastructure and function of mitochondriaBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2009
- Atrazine binds to F1F0-ATP synthase and inhibits mitochondrial function in spermBiochemical and Biophysical Research Communications, 2008
- Reduction of nonspecific protein binding on surface plasmon resonance biosensorsAnalytical and Bioanalytical Chemistry, 2006
- Protein denaturation with guanidine hydrochloride or urea provides a different estimate of stability depending on the contributions of electrostatic interactionsProtein Science, 1994
- F1Fo-ATPase Subunit e Gene Isolated in a Screen for Diet Regulated GenesBiochemical and Biophysical Research Communications, 1993